Early Diagnosis and Preventive Therapy in Parkinson’s Disease
| Other Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Vienna
Springer Vienna
1989, 1989
|
| Edition: | 1st ed. 1989 |
| Series: | Key Topics in Brain Research
|
| Subjects: | |
| Online Access: | |
| Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- Tremor and electrically elicited long-latency reflexes in early stages of Parkinson’s disease
- Evoked potentials in Parkinson’s disease
- Brain mapping of EEG and evoked potentials during physiological aging and in Parkinson’s disease, dementia and depression
- Positron emission tomography in Parkinson’s disease glucose metabolism
- Parkinson’s disease studied using PET
- Pathobiochemistry of the extrapyramidal system: a “short note” review
- Dopaminergic neurotransmission and status of brain iron
- Dopaminergic modulation of neuropeptide gene expression in the rat striatum
- The diagnostic relevance of Lewy bodies and other inclusions in Parkinson’s disease
- Cytoskeletal pathology of the Lewy bodies
- Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitorRo41-0960
- Catecholamines in urine, blood and cerebrospinal fluid
- The premorbid personality of patients with Parkinson’s disease
- Parkinson’s disease: development of dementia in aging
- Psychometric assessment of early signs of dementia in special consideration of Parkinson’s and Alzheimer’s disease — an update
- Sensory and musculo-skeletal dysfunction in Parkinson’s disease—premonitory and permanent
- Autonomic nervous system screening in patients with early Parkinson’s disease
- Clinical and biochemical characteristics of early depression in Parkinson’s disease
- Psychomotor investigations in depressed patients by comparison with Parkinson patients
- Quantitative analysis of voluntary and involuntary motor phenomena in Parkinson’s disease
- Motor performance test
- Measuring body movements in neurological disease, with special reference to Parkinson’s disease
- Long-term measurement of tremor: early diagnostic possibilities
- 3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients
- Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro19-6327
- Aspartate, glutamate, and glutamine in platelets of patients with Parkinson’s disease
- Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease
- The MPTP model: an update
- Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?
- Importance of dopaminergic and GABAergic neurones of the nucleus accumbens and the caudate nucleus for motoricity
- Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?
- Pharmacological and clinical-pharmacological aspects of D1- and D2-receptors
- Chemical modulation of membrane-bound receptors
- Transplantation of dopamine-synthesizing cells — new therapy for Parkinson’s disease?
- L-dopa in Parkinson’s disease
- Pharmacokinetic investigations of various levodopa formulations
- Iron therapy in Parkinson’s disease. Stimulation of endogenous presynaptic L-DOPA biosynthesis by the iron compound oxyferriscorbone
- Provisional experiences with the combination of L-dopa and L-deprenyl
- Clinical pharmacology of amantadine and derivatives
- Dopamine agonist treatment in early Parkinson’s disease
- Subcutaneous apomorphine in Parkinson’s disease
- Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease
- Discussion